Scholarlink

<p>The growing prevalence of antibiotic resistance, coupled with the heightened drug tolerance exhibited by biofilm-associated infections, represents a major public health challenge and demands the development of innovative therapeutic interventions. Probiotics, particularly the genus <i>Lactobacilli</i>, offer an effective, multifaceted strategy that targets biofilm-associated pathogens through competitive exclusion, secretion of antimicrobial metabolites, disruption of quorum sensing, enzymatic degradation of extracellular polymeric substances, and host immunomodulation. Studies demonstrate robust efficacy of probiotics against clinically challenging pathogens, including methicillin-resistant <i>Staphylococcus aureus</i>, multidrug-resistant <i>Pseudomonas aeruginosa</i>, <i>Clostridioides difficile</i>, <i>Helicobacter pylori</i>, and pathogenic <i>Escherichia coli</i>. Postbiotics, particularly cell-free supernatants and purified bacteriocins, offer standardized, shelf-life probiotic products. Notably, synergistic combinations with conventional antibiotics, phytochemicals, or bacteriophages enhance antimicrobial activity while enabling dose-reduction strategies to mitigate the development of resistance. However, compelling preclinical evidence, clinical translation remains constrained by the imperative for strain-specific characterization, methodologically robust randomized controlled trials, and comprehensive safety validation. This study critically mentions current mechanisms underlying <i>Lactobacillus</i>-mediated anti-biofilm strategies and identifies priority research essential to accelerating clinical application. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lactobacillus strains in the prevention and disruption of antimicrobial-resistance in pathogenic microbial biofilms: a review of mechanisms and clinical perspective

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • Maedeh Kiani,
  • Mahtab Mehboodi,
  • Hadis Khanbabaie,
  • Farzaneh Rafie Sedaghat,
  • Faeze Mahdiun,
  • Elham Isaei

摘要

The growing prevalence of antibiotic resistance, coupled with the heightened drug tolerance exhibited by biofilm-associated infections, represents a major public health challenge and demands the development of innovative therapeutic interventions. Probiotics, particularly the genus Lactobacilli, offer an effective, multifaceted strategy that targets biofilm-associated pathogens through competitive exclusion, secretion of antimicrobial metabolites, disruption of quorum sensing, enzymatic degradation of extracellular polymeric substances, and host immunomodulation. Studies demonstrate robust efficacy of probiotics against clinically challenging pathogens, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, Clostridioides difficile, Helicobacter pylori, and pathogenic Escherichia coli. Postbiotics, particularly cell-free supernatants and purified bacteriocins, offer standardized, shelf-life probiotic products. Notably, synergistic combinations with conventional antibiotics, phytochemicals, or bacteriophages enhance antimicrobial activity while enabling dose-reduction strategies to mitigate the development of resistance. However, compelling preclinical evidence, clinical translation remains constrained by the imperative for strain-specific characterization, methodologically robust randomized controlled trials, and comprehensive safety validation. This study critically mentions current mechanisms underlying Lactobacillus-mediated anti-biofilm strategies and identifies priority research essential to accelerating clinical application.